Studies on the stereospecific interaction between aldose reductase and inhibitor

目前世界范围内还没有公认的治疗糖尿病并发症的专门疗法。醛糖还原酶作为预防或延缓并发症发生的药物靶点已显示出良好的效果。人类醛糖还原酶全酶与强效抑制剂非达司他立体异构体的复合物结构将在高分辨率下确定，以阐明导致其抑制能力差异的结合模式。这些结果可能会导致设计出更好的酶抑制剂来治疗糖尿病患者，至少在更好的维持代谢控制的方法被开发出来之前。

There is no therapy specific for treatment of diabetes complications accepted worldwide. The enzyme aldose reductase has shown promising results as a drug target for preventing or delaying the onset of the complications. The structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor Fidarestat will be determined at high resolution in order to elucidate the binding modes responsible for the differences in their inhibitory potencies. The results may lead to the design of better inhibitors of the enzyme for the treatment of diabetes sufferers, at least until better methods for maintaining metabolic control are developed.